Alefacept

Phase 1Terminated

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Aplastic Anemia

Conditions

Aplastic Anemia

Trial Timeline

May 1, 2011 → Apr 16, 2013

NCT ID

NCT01267643

About Alefacept

Alefacept is a phase 1 stage product being developed by Astellas Pharma for Aplastic Anemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT01267643. Target conditions include Aplastic Anemia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01267643	Phase 1	Terminated	May 1, 2011	Apr 16, 2013	Aplastic Anemia
NCT01226420	Phase 2	Terminated	Oct 1, 2010	Aug 1, 2012	Chronic Graft-versus-host Disease
NCT00808223	Phase 2	Completed	Apr 1, 2009	Feb 1, 2012	Psoriasis
NCT00815633	Approved	Terminated	Dec 1, 2008	Mar 1, 2010	Pityriasis Rubra Pilaris
NCT00953329	Approved	Terminated	Feb 1, 2008	Dec 1, 2008	Chronic Plaque Psoriasis
NCT00832585	Approved	Completed	Jan 1, 2008	Oct 1, 2009	Atopic Dermatitis
NCT00658606	Approved	Completed	Oct 1, 2007	Dec 1, 2009	Plaque Psoriasis
NCT00168753	Approved	Completed	Jul 1, 2004	Mar 1, 2005	Moderate to Severe Chronic Plaque Psoriasis
NCT00674063	Phase 3	Completed	Jul 1, 2003	Apr 1, 2004	Chronic Plaque Psoriasis
NCT00692172	Phase 3	Completed	Dec 1, 2001	Nov 1, 2004	Psoriasis

Competing Products

20 competing products in Aplastic Anemia

See all competitors

Product	Company	Stage	Hype Score
CS-7017 + Paclitaxel	Daiichi Sankyo	Phase 1/2	41
efatutazone + paclitaxel	Daiichi Sankyo	Phase 2	52
Romiplostim	Kyowa Kirin	Phase 2/3	65
Lenvatinib 24 mg	Eisai	Phase 2	52
Romiplostim	Kyowa Kirin	Phase 2/3	65
Romiplostim	Kyowa Kirin	Phase 2/3	65
AMG531	Kyowa Kirin	Phase 2	52
Lenvatinib + Nivolumab	Ono Pharmaceutical	Phase 2	52
Hetrombopag Olamine Tablet	Jiangsu Hengrui Medicine	Phase 1	33
Hetrombopag Olamine + Placebo	Jiangsu Hengrui Medicine	Phase 3	77
Trappa ethanolamine tablets ; ciclosporin + Placebo ; ciclosporin	Jiangsu Hengrui Medicine	Phase 2	52
Hetrombopag Olamine Tablet；Ciclosporin Soft Capsule	Jiangsu Hengrui Medicine	Phase 1	33
Hetrombopag Olamine Tablet	Jiangsu Hengrui Medicine	Phase 1	33
Hetrombopag Olamine	Jiangsu Hengrui Medicine	Phase 1/2	41
Hetrombopag Olamine+Standard Therapy + Placebo+Standard Therapy	Jiangsu Hengrui Medicine	Phase 3	77
durvalumab + tremelimumab	AstraZeneca	Phase 1	33
Pembrolizumab	Merck	Phase 2	52
Posaconazole	Merck	Phase 2	52
Cohort 1: hATG, CsA, EPAG Day 14 to Month 6 + Cohort 2: hATG, CsA, EPAG Day 14 to Month 3 + Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6 + Extension Cohort	Novartis	Phase 1/2	41
LDK378 + AUY922	Novartis	Phase 1	33

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved

micafungin + voriconazoleApproved

mirabegron + solifenacinApproved

Zolpidem (Myslee®) + placeboApproved

TacrolimusApproved